Article

Molecular Profiling for Patients With Non-Small Cell Lung Cancer

Heather Wakelee, of Stanford University Medical Center, discusses the importance of molecular profiling in predicting the response of EGFR inhibitors for patients with non-small cell lung cancer.

Heather Wakelee, from Stanford University Medical Center, discusses the importance of molecular profiling in predicting the response of EGFR inhibitors for patients with non-small cell lung cancer (NSCLC).

Molecular profiling is a necessary step beyond the initial diagnosis of NSCLC, Wakelee explains. EGFR mutations are found in about 10 percent of patients, but is often higher in subpopulations.

Current trials are comparing targeted therapies to chemotherapy. Patients are demonstrating better responses and longer progression rates by starting with the appropriate targeted therapy, Wakelee says, if the EGFR or ALK mutation is present.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.